The World Health Organization is to publish two studies looking separately at the usage of monovalent pandemic H1N1 vaccine and the trivalent seasonal influenza jab to take stock of how these vaccines are used around the world. In the.....

ProStrakan's chief executive and director Dr Wilson Totten has resigned after the company revealed it expects to suffer up to £5 million in missed operating profit for the full year as a result of not meeting supply demands for Sancuso (granisetron),.....

Pharming, the Dutch biotech company, has converted private bonds into 7.8 million new shares to improve its capital structure amid the launch of its lead product Rhucin (recombinant human C1 inhibitor).

Pharming issued 5,259,652 shares under a.....

The EMA has approved Merck & Co's Sycrest (asenapine) for the treatment of manic episodes in bipolar 1 disorder in adults. The atypical antipsychotic was approved for manic episodes associated with bipolar 1 disorder, and for.....

Silence Therapeutics' shares opened at 12.5 pence on 7 September, up 75% on the previous day's opening price, after the company announced that it had been approached by an undisclosed company.

Silence said that the approach "may or.....

The EMA has approved Merck/Cardiome's Brinavess (vernakalant) for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults. The move comes only two months after Brinavess was given the nod by the CHMP.....

Two studies into whether bisphosphonates are associated with oesophageal cancer have yielded contradictory conclusions. One published in the BMJ on 3 September.....

Intas Pharmaceuticals of India expects its oncology and oral solids businesses to drive growth as it hopes to scale the Rs20 billion ($429.8 million) turnover mark ahead of its proposed initial public offering (IPO) next year......

The World Health Organization is to publish two studies looking separately at the usage of monovalent pandemic H1N1 vaccine and the trivalent seasonal influenza jab to take stock of how these vaccines are used around the world. In the.....

Japan has publicly disclosed the first reported case of infection with a strain of bacteria carrying the NDM-1 "superbug" gene.

Dokkyo Medical University Hospital in Tochigi prefecture said that a male patient with an Escherichia coli.....

RaQualia Pharma, a Japanese venture spun out from Pfizer research, has reached a licensing deal for two of its pipeline projects with a leading South Korean pharma firm.

The agreement gives CJ CheilJedang exclusive rights in its home market and.....

Aurobindo Pharma of India has entered into a licensing deal with AstraZeneca for the supply of a range of solid dosage and sterile products for emerging markets. The agreement comes months after AstraZeneca struck a similar alliance with India's.....

India is setting up a task force to address various policy-related, inter-ministerial and other issues in the health sector, with the aim of creating a conducive environment for the growth of the domestic pharmaceutical industry.

With the US FDA issuing a rare refusal to file letter for Genentech's (Roche) trastuzumab-DM1 (T-DM1) to treat HER2-positive breast cancer on the basis of a single-arm Phase II trial that it submitted for accelerated approval, the company.....

Novartis and its collaborators have unveiled a new class of promising antimalarials – the spiroindolones. The lead candidate in the class, NITD609, yielded promising efficacy and safety data in in vitro and in vivo.....

Celldex Therapeutics suffered a sharp drop in its share price, wiping almost $40 million off its value to $113 million, following news that Pfizer is terminating their collaboration over rindopepimut, an investigational brain cancer vaccine.....

Glythera is to work with the US FDA's Center for Biologics Evaluation and Research to assess the feasibility of applying the UK-based biotech's PermaLink technology to the generation of synthetic carbohydrate-based conjugate vaccines......

MorphoSys has built further on its extensive history of partnering by gaining access to the Sheffield, UK-based biotech Absynth Biologics' novel target molecules associated with Staphylococcus aureus infections.

The German company's CEO.....

With the US FDA issuing a rare refusal to file letter for Genentech's (Roche) trastuzumab-DM1 (T-DM1) to treat HER2-positive breast cancer on the basis of a single-arm Phase II trial that it submitted for accelerated approval, the company is now.....

Tibotec Pharmaceuticals (J&J) has submitted a marketing authorisation application (MAA) to the EMA for TMC278 (rilpivirine), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV.

The.....